Literature DB >> 6249891

Sensitivity of viruses to phosphorylated 9-(2-hydroxyethoxymethyl)guanine revealed in TK-transformed cells.

G Darby, B A Larder, K F Bastow, H J Field.   

Abstract

Vaccinia and pseudorabies viruses are resistant to ACV [Acyclovir or 9-(2-hydroxyethoxymethyl)guanine] in normal cells. However, both viruses are sensitive in thymidine kinase (TK)-transformed cells in which the resident HSV-specific TK is able to phosphorylate the drug. This demonstrates the sensitivity of these viruses to phosphorylated ACV and suggests a wider antiviral activity for the phosphorylated drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6249891     DOI: 10.1099/0022-1317-48-2-451

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition.

Authors:  J S Gibbs; H C Chiou; K F Bastow; Y C Cheng; D M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

2.  The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.

Authors:  Qiao Meng; Stacy R Hagemeier; Joyce D Fingeroth; Edward Gershburg; Joseph S Pagano; Shannon C Kenney
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

3.  Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.

Authors:  Mark N Prichard; Kathy A Keith; Mary P Johnson; Emma A Harden; Alexis McBrayer; Ming Luo; Shihong Qiu; Debasish Chattopadhyay; Xuesen Fan; Paul F Torrence; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

4.  Cooperative effects between two acyclovir resistance loci in herpes simplex virus.

Authors:  G Darby; M J Churcher; B A Larder
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

Review 5.  A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1.

Authors:  Sara M Thomasy; David J Maggs
Journal:  Vet Ophthalmol       Date:  2016-04-19       Impact factor: 1.644

6.  Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy.

Authors:  H J Field
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

7.  Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus.

Authors:  Hannah M Burgess; Aldo Pourchet; Cristina H Hajdu; Luis Chiriboga; Alan B Frey; Ian Mohr
Journal:  Mol Ther Oncolytics       Date:  2018-01-31       Impact factor: 7.200

8.  Herpes Infections and Dementia: Rebutting Alternative Fact.

Authors:  Richard Lathe; Nian-Sheng Tzeng; Ruth Itzhaki
Journal:  Neurotherapeutics       Date:  2019-01       Impact factor: 7.620

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.